Upadacitinib

In this video, Raj Chovatiya, MD, PhD, discussed research into the Janus kinase inhibitor upadacitinib from the Maui Derm 2024 meeting, examining data into its use in treating atopic dermatitis.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

The mission to understand rheumatoid arthritis inflammation at a molecular level has gained momentum with the rapid evolution of cutting-edge technologies, allowing researchers to delve deeper into the individual differences in inflammatory subtypes.

SAN DIEGO — A novel combination of elsubrutinib and upadacitinib, called ABBV-599, significantly improves systemic lupus erythematosus disease activity and flares through 48 weeks, according to data presented at ACR Convergence 2023.

VANCOUVER, British Columbia — Patients with ulcerative colitis were more likely to achieve clinical response and steroid-free clinical remission at 8 to 16 weeks on upadacitinib vs. ustekinumab, according to a presenter.